톡소플라스마증 : 파이프라인 리뷰

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

톡소플라스마증이란 톡소플라스마 기생충에 의한 감염에 의해 발병하는 질환입니다. 주요 증상으로 온몸 통증과 림프절 비대, 두통·발열·권태감 등이 있습니다. 주요 위험인자에는 HIV/AIDS 및 화학요법, 면역 억제제 등이 포함되어 있습니다. 주요 치료법으로 항말라리아제 및 항생물질 등이 있습니다.

세계 각국의 톡소플라스마증(Toxoplasmosis) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

• 조사 범위

톡소플라스마증 개요

치료제 개발

• 파이프라인 제품 개요
• 파이프라인 제품 비교 분석

톡소플라스마증 : 기업에서 개발중인 치료제

톡소플라스마증 : 대학/연구기관에서 연구중인 치료제

톡소플라스마증 : 파이프라인 제품 개요

• 초기 단계 제품

톡소플라스마증 : 기업에서 개발중인 제품

톡소플라스마증 : 대학/연구기관에서 연구중인 제품

톡소플라스마증 치료제 개발에 참여하고 있는 기업

• Turing Pharmaceuticals AG

톡소플라스마증 : 치료제 평가

• 단독치료 제품(Monotherapy Products)별
• 표적별
• 작용기전별
• 분자 종류별

치료제 개요

톡소플라스마증 : 휴지 상태인 프로젝트

부록

List of Tables

List of Tables

• Number of Products under Development for Toxoplasmosis, 2021
• Number of Products under Development by Companies, 2021
• Number of Products under Development by Universities/Institutes, 2021
• Products under Development by Companies, 2021
• Products under Development by Universities/Institutes, 2021
• Number of Products by Stage and Target, 2021
• Number of Products by Stage and Mechanism of Action, 2021
• Number of Products by Stage and Route of Administration, 2021
• Number of Products by Stage and Molecule Type, 2021
• Toxoplasmosis - Pipeline by AbbVie Inc, 2021
• Toxoplasmosis - Pipeline by GlaxoSmithKline Plc, 2021
• Toxoplasmosis - Pipeline by PGTx Ltd, 2021
• Toxoplasmosis - Pipeline by Tiba Biotech LLC, 2021
• Toxoplasmosis - Pipeline by Vaxinano SE, 2021
• Toxoplasmosis - Pipeline by Vyera Pharmaceuticals LLC, 2021
• Toxoplasmosis - Dormant Projects, 2021

List of Figures

List of Figures

• Number of Products under Development for Toxoplasmosis, 2021
• Number of Products under Development by Companies, 2021
• Number of Products under Development by Universities/Institutes, 2021
• Number of Products by Targets, 2021
• Number of Products by Stage and Targets, 2021
• Number of Products by Mechanism of Actions, 2021
• Number of Products by Stage and Mechanism of Actions, 2021
• Number of Products by Routes of Administration, 2021
• Number of Products by Stage and Routes of Administration, 2021
• Number of Products by Molecule Types, 2021
• Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Drugs In Development, 2021, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.

Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever, and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)

Reasons to Buy:

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

• Introduction
• Global Markets Direct Report Coverage
• Toxoplasmosis - Overview
• Toxoplasmosis - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Toxoplasmosis - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Toxoplasmosis - Companies Involved in Therapeutics Development
• Monoclonal Antibodies for Ocular Toxoplasmosis - Drug Profile
• Toxoplasmosis - Dormant Projects
• Toxoplasmosis - Product Development Milestones
• Featured News & Press Releases
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer